Comparative Pharmacology
Head-to-head clinical analysis: RIOCIGUAT versus VERICIGUAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIOCIGUAT versus VERICIGUAT.
RIOCIGUAT vs VERICIGUAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the nitric oxide (NO) signaling pathway, by sensitizing sGC to endogenous NO and directly stimulating sGC independently of NO. This increases intracellular cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation and inhibition of platelet aggregation.
Vericiguat is a soluble guanylate cyclase (sGC) stimulator. It directly stimulates sGC, enhancing the sensitivity of sGC to endogenous nitric oxide (NO), thereby increasing cyclic guanosine monophosphate (cGMP) production. This leads to smooth muscle relaxation, vasodilation, and inhibition of vascular remodeling and fibrosis.
1 mg orally three times daily for 2 weeks, then increase by 0.5 mg every 2 weeks to target maintenance dose of 2.5 mg three times daily, as tolerated.
1.25 mg orally three times daily with food; increase in 1.25 mg increments every 2 weeks as tolerated to target maintenance dose of 2.5 mg three times daily.
None Documented
None Documented
Clinical Note
moderateRiociguat + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Riociguat."
Clinical Note
moderateRiociguat + Methylphenidate
"Riociguat may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateRiociguat + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Riociguat."
Clinical Note
moderateRiociguat + Erythromycin
Terminal elimination half-life is approximately 7 hours (range 5-12 hours) in patients with pulmonary arterial hypertension. In healthy subjects, half-life is about 5-7 hours. Steady state is achieved within 3-5 days of twice-daily dosing.
The terminal elimination half-life is approximately 4-5 hours in patients with chronic heart failure, allowing twice-daily dosing. In severe renal impairment, half-life may be prolonged (up to 8 hours).
Primarily hepatic metabolism, with minimal renal excretion. Approximately 50-60% of the dose is excreted in feces as metabolites, and about 40-50% in urine as metabolites (4-9% unchanged in urine). Biliary excretion of parent drug is negligible.
Vericiguat is eliminated primarily via non-renal routes, with approximately 53% of the dose recovered in feces and 40% in urine. Renal excretion of unchanged drug is minimal (<5% of the dose).
Category C
Category C
Guanylate Cyclase Stimulator
Guanylate Cyclase Stimulator
"The metabolism of Erythromycin can be decreased when combined with Riociguat."